A Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary blistering disorder due to lack of type VII collagen (C7). At present, treatment is mainly supportive.

Source: Journal of the American Academy of Dermatology - November 27, 2019 Category: Dermatology Authors: Ellie Rashidghamat, Tendai Kadiyirire, Salma Ayis, Gabriela Petrof, Lu Liu, Venu Pullabhatla, Chrysanthi Ainali, Alyson Guy, Sophia Aristodemou, James R. McMillan, Linda Ozoemena, John Mee, Rashida Pramanik, Alka Saxena, Rosamund Nuamah, Emanuele de Rinal Source Type: research